The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 11 July 2006, www.theannals.com, DOI 10.1345/aph.1G645.
 The Annals of Pharmacotherapy: Vol. 40, No. 9, pp. 1635-1639. DOI 10.1345/aph.1G645
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wyatt, K. N
Right arrow Articles by Sheerin, K. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wyatt, K. N
Right arrow Articles by Sheerin, K. A

DRUG INFORMATION ROUNDS

Reduced-Dose Influenza Vaccine

Katleen N Wyatt

PharmD Student, Southern School of Pharmacy, Mercer University, Atlanta, GA

Gina J Ryan, PharmD BCPS CDE

Clinical Assistant Professor, Southern School of Pharmacy, Mercer University

Kathleen A Sheerin, MD

Physician, Atlanta Allergy and Asthma Clinic, Atlanta

Reprints: Dr. Ryan, 3001 Mercer University Dr., Atlanta, GA 30341-4155, fax 678/547-6384, ryan_gj{at}mercer.edu

OBJECTIVE: To evaluate the effectiveness and safety of reduced-dose trivalent inactivated influenza vaccine in adults.

DATA SOURCES: A MEDLINE search was conducted (1966-May 2006) using the key search terms inactivated, trivalent, influenza vaccine, dose, and intradermal.

DATA SYNTHESIS: Four recent studies evaluated the safety and effectiveness of reduced-dose, inactivated, trivalent influenza vaccine. Reduced doses had immunogenicity similar to that of standard dose vaccination in healthy individuals less than 60 years old. Intramuscular administration caused fewer local adverse effects compared with the other routes of administration. The differences in vaccine administration and dosing used in these studies limit the comparison of their results.

CONCLUSIONS: The Centers for Disease Control and Prevention does not recommend vaccinating with reduced-dose influenza vaccine. If reduced-dose vaccination is to be employed during times of vaccine shortage, it should be administered only to healthy adults under the age of 60, and the intramuscular route is preferred.

Key Words: inactivated, influenza vaccine, reduced dose, trivalent

Published Online, July 11, 2006. www.theannals.com, DOI 10.1345/aph.1G645




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.